Form 4: Plus Therapeutics Director Acquires Stock Options

Richard J. Hawkins, a Director at Plus Therapeutics, Inc., acquired stock options and restricted stock units on May 14, 2026.

Summary

• Richard J. Hawkins, a Director of Plus Therapeutics, Inc., reported the acquisition of securities on May 14, 2026.
• The acquisition includes 3,686 Restricted Stock Units (RSUs) and 3,686 stock options.
• The RSUs vest ratably over four quarters, starting July 1, 2026.
• The stock options vest monthly over 12 months from the grant date, with full vesting by the Issuer's 2027 Annual Stockholder Meeting, contingent on continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard executive compensation and insider acquisition, indicating continued commitment rather than a significant strategic shift.

Positives

• Director Richard J. Hawkins has acquired equity in the company, indicating confidence in its future.
• The acquisition of both RSUs and stock options suggests a long-term incentive structure aligned with continued service and company performance.

Risks

• The vesting of RSUs and stock options is contingent on the reporting person's continued service to the Issuer, implying a risk of forfeiture if service is terminated before vesting dates.
• The vesting of stock options is also subject to the Issuer's 2027 Annual Stockholder Meeting, introducing a potential timeline risk for full vesting.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a forward-looking incentive structure tied to continued service and company milestones.

Industry Context

StockSavvy.ai notes that the issuance of stock options and RSUs to directors is a common practice in the biotechnology and pharmaceutical sectors to align executive interests with shareholder value and incentivize long-term commitment.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively, signaling confidence in the company's prospects. The vesting schedules align director incentives with long-term company performance.
• Employees: The structure of equity awards for management can influence overall employee morale and retention strategies.
• Management: The awards provide financial incentives for continued service and performance.

Next Steps

• Vesting of Restricted Stock Units over four quarters commencing July 1, 2026.
• Monthly vesting of stock options over 12 months from the grant date, with full vesting by the 2027 Annual Stockholder Meeting.

Key Dates

Keywords

Plus Therapeutics, PSTV, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director, SEC Filing, Equity Award